FindTrial
Sign In

Camostat

DRUG6 trials

Sponsors

Cancer Research UK, National Institute of Allergy and Infectious Diseases (NIAID), University Hospital, Ghent, Stanford University, KU Leuven

Conditions

COVID-19 InfectionCoronavirusCovid19SARS-CoV Infection

Phase 2

A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)
TerminatedNCT04455815
Cancer Research UKCOVID-19 Infection
Start: 2020-09-23End: 2022-03-03Updated: 2023-12-11
ACTIV-2: A Study for Outpatients With COVID-19
CompletedNCT04518410
National Institute of Allergy and Infectious Diseases (NIAID)Coronavirus, Covid19
Start: 2020-08-19End: 2023-06-20Updated: 2024-08-02
The Potential of Camostat in COVID-19
TerminatedNCT04625114
University Hospital, GhentCovid19
Start: 2020-11-04End: 2022-07-12Updated: 2024-08-09
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol
TerminatedNCT04662073
Stanford UniversityCovid19
Start: 2021-04-23End: 2022-03-04Updated: 2023-06-28
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol
CompletedNCT04662086
Stanford UniversityCovid19
Start: 2021-04-23End: 2023-02-02Updated: 2023-06-28

Phase 3

The DAWN Antivirals Trial for Ambulatory COVID-19 Patients
TerminatedNCT04730206
KU LeuvenCovid19, SARS-CoV Infection
Start: 2021-06-15End: 2022-07-13Updated: 2022-10-03

Related Papers

Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19
UNC Libraries2025-02-05
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection
UNC Libraries2025-02-05
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial
UNC Libraries2025-02-05
Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial
UNC Libraries2025-02-05
Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials
UNC Libraries2025-02-05
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
UNC Libraries2025-02-05
Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response
UNC Libraries2024-10-03
Variant-Specific Viral Kinetics in Acute COVID-19
UNC Libraries2024-09-01
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial
UNC Libraries2024-09-01
Immune Status and SARS-CoV-2 Viral Dynamics
UNC Libraries2024-09-01
Long COVID After Bamlanivimab Treatment
UNC Libraries2024-09-01
Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response
Pathogens and Immunity2024-08-212 citations
Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial
The Journal of Infectious Diseases2024-07-181 citations
SARS-CoV-2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With COVID-19
Clinical Infectious Diseases2024-07-172 citations
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019
UNC Libraries2023-10-11
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial.
2023-10-069 citations
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.
2023-10-0114 citations
ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients
The Journal of Infectious Diseases2023-08-3112 citations
Immune Status and SARS-CoV-2 Viral Dynamics
The Journal of Infectious Diseases2023-08-3112 citations
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial
The Journal of Infectious Diseases2023-08-318 citations

19 more papers not shown